Wall Street analysts expect Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) to report earnings of ($0.04) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Amphastar Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.30) and the highest estimate coming in at $0.10. Amphastar Pharmaceuticals reported earnings of $0.01 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 500%. The firm is expected to issue its next quarterly earnings report on Monday, March 12th.
According to Zacks, analysts expect that Amphastar Pharmaceuticals will report full-year earnings of $0.23 per share for the current year, with EPS estimates ranging from ($0.03) to $0.38. For the next fiscal year, analysts expect that the firm will report earnings of $0.57 per share, with EPS estimates ranging from $0.11 to $0.86. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.05. The company had revenue of $57.90 million for the quarter, compared to analyst estimates of $57.23 million. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The firm’s quarterly revenue was down 9.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.14 EPS.
Amphastar Pharmaceuticals (NASDAQ:AMPH) traded down $0.09 during trading on Friday, reaching $19.37. 111,964 shares of the company’s stock were exchanged, compared to its average volume of 162,149. The firm has a market cap of $894.69, a price-to-earnings ratio of 129.73, a PEG ratio of 1.37 and a beta of 1.69. Amphastar Pharmaceuticals has a 12 month low of $12.05 and a 12 month high of $19.95. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.86 and a current ratio of 3.08.
In other news, Director Stephen B. Shohet sold 7,866 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $18.87, for a total value of $148,431.42. Following the sale, the director now owns 31,982 shares of the company’s stock, valued at $603,500.34. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO William J. Peters sold 6,226 shares of Amphastar Pharmaceuticals stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $19.67, for a total transaction of $122,465.42. The disclosure for this sale can be found here. Insiders sold a total of 72,787 shares of company stock worth $1,359,684 over the last ninety days. Insiders own 11.10% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 10.8% in the second quarter. Vanguard Group Inc. now owns 2,414,797 shares of the company’s stock valued at $43,128,000 after purchasing an additional 235,033 shares during the period. Dimensional Fund Advisors LP raised its position in Amphastar Pharmaceuticals by 17.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock worth $27,844,000 after acquiring an additional 226,271 shares during the last quarter. Teachers Advisors LLC raised its position in Amphastar Pharmaceuticals by 1.1% during the second quarter. Teachers Advisors LLC now owns 549,149 shares of the company’s stock worth $9,808,000 after acquiring an additional 6,196 shares during the last quarter. Northern Trust Corp raised its position in Amphastar Pharmaceuticals by 2.0% during the second quarter. Northern Trust Corp now owns 485,706 shares of the company’s stock worth $8,675,000 after acquiring an additional 9,672 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in Amphastar Pharmaceuticals by 143.0% during the second quarter. UBS Asset Management Americas Inc. now owns 362,947 shares of the company’s stock worth $6,482,000 after acquiring an additional 213,572 shares during the last quarter. Hedge funds and other institutional investors own 44.14% of the company’s stock.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.